Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Bladder Cancer

  Free Subscription


1 Adv Urol
4 Aktuelle Urol
1 Anticancer Agents Med Chem
1 Appl Radiat Isot
2 Arch Pathol Lab Med
1 Biochim Biophys Acta Rev Cancer
1 Biomedicines
1 Brief Bioinform
1 Cancer Gene Ther
1 Cancer Med
2 Cancers (Basel)
1 Cell Biochem Biophys
2 Cell Mol Biol (Noisy-le-grand)
1 Cell Rep
1 Cell Signal
1 Chem Biol Drug Des
1 Cureus
1 Curr Pharm Biotechnol
1 EBioMedicine
1 Eur J Med Res
1 Eur Urol
1 Front Immunol
2 Front Med (Lausanne)
3 Front Oncol
3 Heliyon
1 Int J Mol Sci
1 Int J Urol
1 Ir J Med Sci
1 J Biomed Res
2 J Cancer
1 J Clin Neurosci
1 J Immunother
1 J Med Case Rep
1 JNCI Cancer Spectr
1 Kaohsiung J Med Sci
1 Med Image Anal
1 Mol Biotechnol
1 Mol Cancer Ther
1 Mol Med Rep
1 Nat Commun
1 Nat Prod Res
1 Pathologie (Heidelb)
2 Photodiagnosis Photodyn Ther
1 Probiotics Antimicrob Proteins
1 Support Care Cancer
1 Technol Cancer Res Treat
2 Urol Oncol
2 Urologia
1 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Adv Urol

  1. NISHIMURA N, Miyake M, Miyamoto T, Shimizu T, et al
    Routine Surveillance of Upper Urinary Tract Imaging for Diagnosing Upper Urinary Tract Urothelial Cancer Recurrence in Patients with Nonmuscle Invasive Bladder Cancer.
    Adv Urol. 2024;2024:5894288.
    PubMed         Abstract available

    Aktuelle Urol

  2. HERRMANN J, Hartung FO, Kriegmair MC, Becker B, et al
    [Should we all switch to en-bloc resection of bladder tumours?].
    Aktuelle Urol. 2024;55:250-254.
    PubMed         Abstract available

  3. [Not Available].
    Aktuelle Urol. 2024;55:192-194.

  4. [Not Available].
    Aktuelle Urol. 2024;55:194.

  5. [Not Available].
    Aktuelle Urol. 2024;55:202-204.

    Anticancer Agents Med Chem

  6. LI Z, Yang J, Chen L, Chen P, et al
    Moscatilin Reverses EMT Progression and its Resulting Enhanced Invasion and Migration by Affecting the TGF-beta Signaling Pathway in Bladder Cancer.
    Anticancer Agents Med Chem. 2024.
    PubMed         Abstract available

    AORN J

  7. ROBISON M, Bush NJ
    Clamp for Safety: Improving Intravesical Chemotherapy Practices.
    AORN J. 2024;119:412-420.
    PubMed         Abstract available

    Appl Radiat Isot

  8. KANMALAR M, Kamal R, Abdul Sani SF, Pathmanathan D, et al
    Spectroscopic diagnosis and metabolite characterization of cisplatin resistance regulated by FDFT1 in bladder cancer tissue.
    Appl Radiat Isot. 2024;210:111372.
    PubMed         Abstract available

    Arch Pathol Lab Med

  9. RUSSELL DH, Epstein JI, Kryvenko ON, Schlumbrecht M, et al
    Adenocarcinomas of the Gynecologic Tract Involving the Urinary Bladder: A Series of 16 Cases Potentially Mimicking Urothelial Malignancy.
    Arch Pathol Lab Med. 2024;148:705-714.
    PubMed         Abstract available

  10. ABDULFATAH E, Kunju LP
    Diagnostic Approach to and Differential Diagnosis of Clear Cell and Glandular Lesions of the Lower Urinary Tract.
    Arch Pathol Lab Med. 2024;148:642-648.
    PubMed         Abstract available

    Biochim Biophys Acta Rev Cancer

  11. PICARD LC, Rich FJ, Kenwright DN, Stevens AJ, et al
    Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer.
    Biochim Biophys Acta Rev Cancer. 2024 May 26:189123.
    PubMed         Abstract available


  12. STOJNEV S, Conic I, Ristic Petrovic A, Petkovic I, et al
    The Association of Death Receptors and TGF-beta1 Expression in Urothelial Bladder Cancer and Their Prognostic Significance.
    Biomedicines. 2024;12:1123.
    PubMed         Abstract available

    Brief Bioinform

  13. WU J, Zhao X, He Y, Pan B, et al
    IDMIR: identification of dysregulated miRNAs associated with disease based on a miRNA-miRNA interaction network constructed through gene expression data.
    Brief Bioinform. 2024;25:bbae258.
    PubMed         Abstract available

    Cancer Gene Ther

  14. LIU C, Zou Z, Lu S, Jin K, et al
    CircPKN2 promotes ferroptosis in bladder cancer by promoting the ubiquitination of Stearoyl-CoA Desaturase 1.
    Cancer Gene Ther. 2024 May 27. doi: 10.1038/s41417-024-00784.
    PubMed         Abstract available

    Cancer Med

  15. LI DX, Yu QX, Wu RC, Wang J, et al
    Efficiency of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer: An umbrella review.
    Cancer Med. 2024;13:e7323.
    PubMed         Abstract available

    Cancers (Basel)

  16. BLICHERT-REFSGAARD L, Graugaard-Jensen C, Norgaard M, Jensen JB, et al
    Use of Bladder-Related Medication in Non-Muscle Invasive Bladder Cancer Patients.
    Cancers (Basel). 2024;16:1936.
    PubMed         Abstract available

  17. MCNALL S, Hooper K, Sullivan T, Rieger-Christ K, et al
    Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review.
    Cancers (Basel). 2024;16:1843.
    PubMed         Abstract available

    Cell Biochem Biophys

  18. LI CC, Tsai BC, Annseles Rajula S, Hsu CH, et al
    Tannic Acid Impedes the Proliferation of Bladder Cancer Cells by Elevating Mitochondrial Pathways of Apoptosis.
    Cell Biochem Biophys. 2024 May 29. doi: 10.1007/s12013-024-01286.
    PubMed         Abstract available

    Cell Mol Biol (Noisy-le-grand)

  19. MUSLUM O, Ahmet K, Ebru O, Ahmet T, et al
    Impacts of Chlorine 1-3 ion channels on localized bladder neoplasms.
    Cell Mol Biol (Noisy-le-grand). 2024;70:76-81.
    PubMed         Abstract available

  20. YU X, Liao B, Du Z, Zhu P, et al
    EGFR/TKIs induce excessive apoptosis of bladder carcinoma cells by arresting cell cycle and promoting mitochondrial peroxidation damage.
    Cell Mol Biol (Noisy-le-grand). 2024;70:258-262.
    PubMed         Abstract available

    Cell Rep

  21. LEE S, Bondaruk J, Wang Y, Chen H, et al
    Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.
    Cell Rep. 2024;43:114146.
    PubMed         Abstract available

    Cell Signal

  22. WANG X, Jin L, Zhang X, Li M, et al
    Transcriptomic profiling and risk assessment in bladder cancer: Insights from copper death-related genes.
    Cell Signal. 2024 May 27:111237. doi: 10.1016/j.cellsig.2024.111237.
    PubMed         Abstract available

    Chem Biol Drug Des

  23. YANG Z, Guo R, Bi Y, Xu W, et al
    Peimenine unleashes therapeutic promise in urothelial bladder cancer: inhibition of proliferation, induction of cell death and modulation of key pathways.
    Chem Biol Drug Des. 2024;103:e14528.
    PubMed         Abstract available


  24. AVCI MA, Arslan B, Arslan O, Ozdemir E, et al
    The Role of Thrombocyte/Lymphocyte Ratio and Aspartate Transaminase/Alanine Transaminase (De Ritis) Ratio in Prediction of Recurrence and Progression in Non-muscle Invasive Bladder Cancer.
    Cureus. 2024;16:e59299.
    PubMed         Abstract available

    Curr Pharm Biotechnol

  25. BANSAL K, Chaudhary N, Bhati H, Vanshita, et al
    Unveiling FDA-Approved Drugs and Formulations in the Management of Bladder Cancer: A Review.
    Curr Pharm Biotechnol. 2024 May 23. doi: 10.2174/0113892010314650240514053735.
    PubMed         Abstract available


  26. WONG JKM, McCulloch TR, Alim L, Omer N, et al
    TGF-beta signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.
    EBioMedicine. 2024;104:105176.
    PubMed         Abstract available

    Eur J Med Res

  27. XIAO S, Chen J, Wei Y, Song W, et al
    BHLHE41 inhibits bladder cancer progression via regulation of PYCR1 stability and thus inactivating PI3K/AKT signaling pathway.
    Eur J Med Res. 2024;29:302.
    PubMed         Abstract available

    Eur Urol

  28. BABJUK M
    Can an En Bloc Technique Improve Outcomes of Endoscopic Surgery for Non-muscle-invasive Bladder Cancer?
    Eur Urol. 2024 May 25:S0302-2838(24)02382-0. doi: 10.1016/j.eururo.2024.

    Front Immunol

  29. YOON AR, Jiao A, Hong J, Kim B, et al
    Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3beta inhibitor enhances antitumor immune response against bladder cancer.
    Front Immunol. 2024;15:1360436.
    PubMed         Abstract available

    Front Med (Lausanne)

  30. SAVCHENKO E, Bunimovich-Mendrazitsky S
    Investigation toward the economic feasibility of personalized medicine for healthcare service providers: the case of bladder cancer.
    Front Med (Lausanne). 2024;11:1388685.
    PubMed         Abstract available

  31. BALCIK OY, Demir B, Ilhan Y, Akagunduz B, et al
    Geriatric nutritional risk index and controller nutritional status score before metastatic first-line chemotherapy predict survival in patients over 70 years of age with metastatic bladder cancer.
    Front Med (Lausanne). 2024;11:1376607.
    PubMed         Abstract available

    Front Oncol

  32. DAVIS K, Orf J, Ballon-Landa E, Hamilton Z, et al
    Neoadjuvant chemotherapy prior to radical cystectomy for non-muscle invasive bladder cancer: national trends and pathologic outcomes.
    Front Oncol. 2024;14:1392062.
    PubMed         Abstract available

  33. QIAO Y, Jia Y, Luo L, Li B, et al
    Development and validation of a nomogram to predict lymph node metastasis in patients with progressive muscle-invasive bladder cancer.
    Front Oncol. 2024;14:1342244.
    PubMed         Abstract available

  34. GHALI F, Holt SK, Koehne EL, Chen JJ, et al
    Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older.
    Front Oncol. 2024;14:1341655.
    PubMed         Abstract available


  35. ZHANG W, Liang ZQ, He RQ, Huang ZG, et al
    The upregulation and transcriptional regulatory mechanisms of Extra spindle pole bodies like 1 in bladder cancer: An immunohistochemistry and high-throughput screening Evaluation.
    Heliyon. 2024;10:e31192.
    PubMed         Abstract available

  36. QIU D, Zhao B, Wang W, Zheng G, et al
    The predictive value of PFKFB3 in bladder cancer prognosis.
    Heliyon. 2024;10:e31347.
    PubMed         Abstract available

  37. CHATTERJEE D, Heeamoni SA, Sultana T, Mou SI, et al
    Delineating the mechanistic relevance of the TP53 gene and its mutational impact on gene expression and patients' survival in bladder cancer.
    Heliyon. 2024;10:e31286.
    PubMed         Abstract available

    Int J Mol Sci

  38. LIN YH, Chen TM, Tsai YL, Tsai WC, et al
    The Reduction of PSMB4 in T24 and J82 Bladder Cancer Cells Inhibits the Angiogenesis and Migration of Endothelial Cells.
    Int J Mol Sci. 2024;25:5559.
    PubMed         Abstract available

    Int J Urol

  39. MITSUI Y, Okawa M, Hori S, Uetani M, et al
    Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15509.
    PubMed         Abstract available

    Ir J Med Sci

  40. RONAN K, Jordan E, Leonard C, McDermott R, et al
    Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
    Ir J Med Sci. 2024;193:1155-1161.
    PubMed         Abstract available

    J Biomed Res

  41. WANG P, Wei X, Qu X, Zhu Y, et al
    Potential clinical application of microRNAs in bladder cancer.
    J Biomed Res. 2024 Jan 25:1-18. doi: 10.7555/JBR.37.20230245.
    PubMed         Abstract available

    J Cancer

  42. WANG T, Wang G, Shan D, Fang Y, et al
    ACAT1 promotes proliferation and metastasis of bladder cancer via AKT/GSK3beta/c-Myc signaling pathway.
    J Cancer. 2024;15:3297-3312.
    PubMed         Abstract available

  43. YU X, Li S, Ke S, Ye C, et al
    CSF2 Impairs Nrf2 Signaling through the Akt/Mtor Pathway in the Development of Bladder Cancer.
    J Cancer. 2024;15:3242-3253.
    PubMed         Abstract available

    J Clin Neurosci

  44. ONDER T, Karacin C, Kekilli E, Goksel F, et al
    Predicting survival after brain metastases in patients with bladder cancer.
    J Clin Neurosci. 2024;125:146-151.
    PubMed         Abstract available

    J Immunother

  45. LI B, Jin K, Liu Z, Su X, et al
    RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
    J Immunother. 2024 May 27. doi: 10.1097/CJI.0000000000000525.
    PubMed         Abstract available

    J Med Case Rep

  46. MIYAZAKI T, Taguchi S, Obata N, Mizobuchi S, et al
    Severe hypotension and postoperative cardiac arrest caused by 5-aminolevulinic acid: a case report.
    J Med Case Rep. 2024;18:264.
    PubMed         Abstract available

    JNCI Cancer Spectr

  47. NECCHI A, Ramlau R, Falcon Gonzalez A, Chaudhry A, et al
    Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
    JNCI Cancer Spectr. 2024;8:pkae030.
    PubMed         Abstract available

    Kaohsiung J Med Sci

  48. YANG FK, Tian C, Zhou LX, Guan TY, et al
    The value of urinary exosomal microRNA-21 in the early diagnosis and prognosis of bladder cancer.
    Kaohsiung J Med Sci. 2024 May 27. doi: 10.1002/kjm2.12845.
    PubMed         Abstract available

    Med Image Anal

  49. YUE X, Huang X, Xu Z, Chen Y, et al
    Involving logical clinical knowledge into deep neural networks to improve bladder tumor segmentation.
    Med Image Anal. 2024;95:103189.
    PubMed         Abstract available

    Mol Biotechnol

  50. SHI W, Dong J, Zhong B, Hu X, et al
    Predicting the Prognosis of Bladder Cancer Patients Through Integrated Multi-omics Exploration of Chemotherapy-Related Hypoxia Genes.
    Mol Biotechnol. 2024 May 28. doi: 10.1007/s12033-024-01203.
    PubMed         Abstract available

    Mol Cancer Ther

  51. SEREMAK JR, Gupta KB, Bonigala S, Liu E, et al
    Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy.
    Mol Cancer Ther. 2024 May 30. doi: 10.1158/1535-7163.MCT-23-0806.
    PubMed         Abstract available

    Mol Med Rep

  52. LIAO YX, Zeng JM, Zhou JJ, Yang GH, et al
    [Retracted] Silencing of RTKN2 by siRNA suppresses proliferation, and induces G1 arrest and apoptosis in human bladder cancer cells.
    Mol Med Rep. 2024;30:134.
    PubMed         Abstract available

    Nat Commun

  53. DRESSLER FF, Diedrichs F, Sabtan D, Hinrichs S, et al
    Proteomic analysis of the urothelial cancer landscape.
    Nat Commun. 2024;15:4513.
    PubMed         Abstract available

    Nat Prod Res

  54. GHANADIAN M, Aghaei M, Akhavan Roofigar A, Ayatollahi SA, et al
    Discovery of new 13(17)-epoxymyrsinane diterpenes from aerial flowering parts of euphorbia spinidens Bornm. ex Prokh. with proapoptotic activities against human bladder cancer EJ138 cells.
    Nat Prod Res. 2024 May 30:1-8. doi: 10.1080/14786419.2024.2358389.
    PubMed         Abstract available

    Pathologie (Heidelb)

    [Mimickers and diagnostic pitfalls of urinary bladder cancer].
    Pathologie (Heidelb). 2024 May 30. doi: 10.1007/s00292-024-01335.
    PubMed         Abstract available

    Photodiagnosis Photodyn Ther

  56. SUZUKI S, Nagumo Y, Ikeda A, Kojo K, et al
    Patient characteristics correlate with diagnostic performance of photodynamic diagnostic assisted transurethral resection of bladder tumors: A retrospective, single-center study.
    Photodiagnosis Photodyn Ther. 2024;46:104052.
    PubMed         Abstract available

  57. NAKAGAWA R, Nohara T, Kano H, Makino T, et al
    Does the quality of endoscopic equipment influence the recurrence rate after photodynamic diagnosis-assisted transurethral resection of bladder tumor?
    Photodiagnosis Photodyn Ther. 2024;46:104023.
    PubMed         Abstract available

    Probiotics Antimicrob Proteins

  58. CHANG CF, Chang PC, Lee YC, Pan CY, et al
    The Antimicrobial Peptide Tilapia Piscidin 4 Induced the Apoptosis of Bladder Cancer Through ERK/SIRT1/PGC-1alpha Signaling Pathway.
    Probiotics Antimicrob Proteins. 2024 May 28. doi: 10.1007/s12602-024-10296.
    PubMed         Abstract available

    Support Care Cancer

  59. CALOUDAS AB, Haltom TM, Goltz HH, Badr HJ, et al
    Patient-centered development of a bladder cancer survivorship care plan.
    Support Care Cancer. 2024;32:397.
    PubMed         Abstract available

    Technol Cancer Res Treat

  60. FAHOUM I, Naamneh R, Silberberg K, Hagege R, et al
    Detection of Muscularis propria Invasion in Urothelial Carcinoma Using Artificial Intelligence.
    Technol Cancer Res Treat. 2024;23:15330338241257479.
    PubMed         Abstract available

    Urol Oncol

  61. MASSARI M, O'Malley P, Benidir T, Su LM, et al
    Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
    Urol Oncol. 2024 May 26:S1078-1439(24)00465.
    PubMed         Abstract available

  62. ABOU CHAKRA M, McElree IM, Packiam VT, Mott SL, et al
    Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer.
    Urol Oncol. 2024 May 24:S1078-1439(24)00464.
    PubMed         Abstract available


  63. SINHA S, Choudhury S, Mishra J, Kundu G, et al
    A study on immunohistochemical expression of HER2/Neu and p63 and its association with grade and invasiveness in case of bladder carcinoma.
    Urologia. 2024;91:284-288.
    PubMed         Abstract available

  64. BASIRI A, Zahir M, Soleimani M, Khoshdel AR, et al
    Comparison of different urinary diversions after radical cystectomy in Iran: Assessment of health-related quality of life and financial burden in a Middle Eastern country.
    Urologia. 2024;91:276-283.
    PubMed         Abstract available

    World J Urol

  65. HEERS H, Gut JM, Hofmann R, Flegar L, et al
    Pilot study for bladder cancer detection with volatile organic compounds using ion mobility spectrometry: a novel urine-based approach.
    World J Urol. 2024;42:353.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.